Showing 12,581 - 12,600 results of 17,107 for search '(( 59 ((0 decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (mean decrease)) ))', query time: 0.98s Refine Results
  1. 12581
  2. 12582
  3. 12583
  4. 12584
  5. 12585
  6. 12586
  7. 12587
  8. 12588

    Table_1_Temporal trend of age at menarche in Korean females born between 1927 and 2004: a population-based study.docx by Da Hye Lee (5284475)

    Published 2024
    “…The trend in age at menarche was analyzed according to 15 birth-year groups (with 5-year intervals) using quantile regression analysis.</p>Results<p>The mean age at menarche decreased from 16.92 ± 0.06 years for females born before 1935 to 12.45 ± 0.04 years for females born between 2000 and 2004 (p <.001). …”
  9. 12589
  10. 12590

    Evaluation of CD data. by Anna Gaertner (127899)

    Published 2012
    “…The results are presented as means±SEM [%] for three independent measurements. α-helical content (<b>A</b>) was 5.9±0.8 and 5.9±0.5 without Ca<sup>2+</sup> (-Ca<sup>2+</sup>) and 3.2±1.4 and 3.2±0.2 with 5 mM CaCl<sub>2</sub> for rECD-wt-nat and rECD-wt-denat, respectively. β-strand content (<b>B</b>) was 38.2±0.3 and 36.6±1.3 without Ca<sup>2+</sup> and 40.5±0.8 and 40.7±0.6 with 5 mM CaCl<sub>2</sub>. …”
  11. 12591
  12. 12592
  13. 12593
  14. 12594
  15. 12595

    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Our updated analysis confirmed at PC therapy significantly improves OS (hazard ratio [HR]: 0.73 [0.69, 0.77], P < 0.00001), PFS (HR: 0.56 [0.52, 0.60], P < 0.00001), duration of response (DOR, HR: 0.50 [0.45, 0.54], P < 0.00001) and objective response rate (ORR, risk ratio [RR]: 1.59 [1.51, 1.67], P < 0.00001) compared to chemotherapy alone. …”
  16. 12596

    Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Our updated analysis confirmed at PC therapy significantly improves OS (hazard ratio [HR]: 0.73 [0.69, 0.77], P < 0.00001), PFS (HR: 0.56 [0.52, 0.60], P < 0.00001), duration of response (DOR, HR: 0.50 [0.45, 0.54], P < 0.00001) and objective response rate (ORR, risk ratio [RR]: 1.59 [1.51, 1.67], P < 0.00001) compared to chemotherapy alone. …”
  17. 12597
  18. 12598
  19. 12599
  20. 12600